ALLARITY THERAPEUTICS INC (ALLR) Stock Overview
NASDAQ:ALLR - US0167445008 - Common Stock
ALLR Key Statistics, Chart & Performance
The current stock price of ALLR is 1.56 USD. In the past month the price increased by 34.91%. In the past year, price decreased by -73.74%.
ALLR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.74 | 369.26B | ||
| AMGN | AMGEN INC | 13.18 | 154.73B | ||
| GILD | GILEAD SCIENCES INC | 14.78 | 141.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 99.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 62.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.20B | ||
| ARGX | ARGENX SE - ADR | 75.99 | 43.11B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.03 | 35.48B | ||
| INSM | INSMED INC | N/A | 28.12B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.54B | ||
| NTRA | NATERA INC | N/A | 22.44B | ||
| BIIB | BIOGEN INC | 8.53 | 20.02B |
Related stock screener links
About ALLR
Company Profile
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Company Info
ALLARITY THERAPEUTICS INC
24 School St., 2Nd Floor
Boston MASSACHUSETTS US
Employees: 7
Phone: 14014264664
ALLARITY THERAPEUTICS INC / ALLR FAQ
What is the stock price of ALLARITY THERAPEUTICS INC today?
The current stock price of ALLR is 1.56 USD. The price increased by 9.09% in the last trading session.
What is the ticker symbol for ALLARITY THERAPEUTICS INC stock?
The exchange symbol of ALLARITY THERAPEUTICS INC is ALLR and it is listed on the Nasdaq exchange.
On which exchange is ALLR stock listed?
ALLR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALLARITY THERAPEUTICS INC stock?
7 analysts have analysed ALLR and the average price target is 9.18 USD. This implies a price increase of 488.46% is expected in the next year compared to the current price of 1.56. Check the ALLARITY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALLARITY THERAPEUTICS INC worth?
ALLARITY THERAPEUTICS INC (ALLR) has a market capitalization of 23.52M USD. This makes ALLR a Nano Cap stock.
How many employees does ALLARITY THERAPEUTICS INC have?
ALLARITY THERAPEUTICS INC (ALLR) currently has 7 employees.
What are the support and resistance levels for ALLARITY THERAPEUTICS INC (ALLR) stock?
ALLARITY THERAPEUTICS INC (ALLR) has a support level at 1. Check the full technical report for a detailed analysis of ALLR support and resistance levels.
Should I buy ALLARITY THERAPEUTICS INC (ALLR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALLR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALLR, evaluating the profitability, health, valuation and growth aspects
- ALLARITY THERAPEUTICS INC (ALLR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALLARITY THERAPEUTICS INC (ALLR) Sales and EPS estimates to see what analysts future expectations are.
- ALLARITY THERAPEUTICS INC (ALLR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALLARITY THERAPEUTICS INC (ALLR) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALLARITY THERAPEUTICS INC (ALLR) Stock Chart to make your own analysis
- ALLARITY THERAPEUTICS INC (ALLR) Latest news and press-releases to stay up to date.
Does ALLARITY THERAPEUTICS INC (ALLR) stock pay dividends?
ALLR does not pay a dividend.
What is the Price/Earnings (PE) ratio of ALLARITY THERAPEUTICS INC (ALLR)?
ALLARITY THERAPEUTICS INC (ALLR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-123690).
What is the Short Interest ratio of ALLARITY THERAPEUTICS INC (ALLR) stock?
The outstanding short interest for ALLARITY THERAPEUTICS INC (ALLR) is 3.76% of its float. Check the ownership tab for more information on the ALLR short interest.
ALLR Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ALLR. When comparing the yearly performance of all stocks, ALLR is a bad performer in the overall market: 77.34% of all stocks are doing better.
ALLR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALLR. The financial health of ALLR is average, but there are quite some concerns on its profitability.
ALLR Financial Highlights
Over the last trailing twelve months ALLR reported a non-GAAP Earnings per Share(EPS) of -123690. The EPS increased by 87.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -116.28% | ||
| ROE | -202.65% | ||
| Debt/Equity | 0 |
ALLR Forecast & Estimates
7 analysts have analysed ALLR and the average price target is 9.18 USD. This implies a price increase of 488.46% is expected in the next year compared to the current price of 1.56.